AI ‐ NLME : A New Artificial Intelligence‐Driven Nonlinear Mixed Effect Modeling Approach for Analyzing Longitudinal Data in Randomized Placebo‐Controlled Clinical Trials

Documenti analoghi

• Comparison of Different Machine Learning Methodologies for Predicting the Non‐Specific Treatment Response in Placebo Controlled Major Depressive Disorder Clinical Trials
  di: Roberto Gomeni, et al.
  Pubblicazione: (2025)
• Deep‐Learning‐ versus Hypothesis‐Driven Modeling in Model‐Informed Drug Development: A PK/PD Case Study
  di: Roberto Gomeni, et al.
  Pubblicazione: (2026)
• Modulating Placebo Effects in Clinical Trials: Study Team Briefing to Optimize Drug–Placebo Differences
  di: Martin Coenen, et al.
  Pubblicazione: (2025)
• Safety, Tolerability, and Pharmacokinetics of NIM‐1324 an Oral LANCL2 Agonist in a Randomized, Double‐Blind, Placebo‐Controlled Phase I Clinical Trial
  di: Andrew Leber, et al.
  Pubblicazione: (2025)
• First‐In‐Human, Randomized, Placebo‐Controlled, SAD and MAD Trial to Evaluate Safety, Tolerability, and PK/PD Modeling of Potravitug in Healthy Adults
  di: Marcus May, et al.
  Pubblicazione: (2025)